Enlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025

Reuters

2025/06/10

Enlivex <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has announced that it will present clinical data from its ongoing study of Allocetra™, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra™ in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465860-en) on June 10, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542331490"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542331490\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542331490?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-10 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542331490","market":"us","top_or_hot":-1,"title":"Enlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enlivex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENLV\">Enlivex Therapeutics Ltd.</a> (Nasdaq: ENLV) has announced that it will present clinical data from its ongoing study of Allocetra™, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra™ in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465860-en) on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-10 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enlivex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENLV\">Enlivex Therapeutics Ltd.</a> (Nasdaq: ENLV) has announced that it will present clinical data from its ongoing study of Allocetra™, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra™ in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465860-en) on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL4N1hkK:1","article_id":"2542331490","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542331490","pubTimestamp":1749558772,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Enlivex Therapeutics Ltd.  has announced that it will present clinical data from its ongoing study of Allocetra, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology  European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","ENLV":"Enlivex Therapeutics Ltd.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Enlivex Therapeutics宣布在EULAR 2025上展示有希望的Allocetra™膝骨关节炎临床试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENLV":0.9,"NDAQ":0.9},"content_text":"Enlivex Therapeutics Announces Presentation of Promising Allocetra™ Clinical Trial Data in Knee Osteoarthritis at EULAR 2025\n    \n\nEnlivex Therapeutics Ltd. (Nasdaq: ENLV) has announced that it will present clinical data from its ongoing study of Allocetra™, a macrophage reprogramming cell therapy, at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology. The conference is scheduled to take place from June 11-14, 2025, in Barcelona, Spain. The presentation will feature data from a Phase I/II trial evaluating Allocetra™ in patients with knee osteoarthritis. The therapy has shown promising results in terms of safety and efficacy, including pain reduction and improved joint function. The company has completed patient enrollment for the Phase II stage of the trial and anticipates releasing topline data by August 2025. Enlivex representatives, including CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi, will attend the conference to engage with stakeholders and the scientific community.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465860-en) on June 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}